BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32446166)

  • 1. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.
    Ejegod DM; Hansen M; Christiansen IK; Pedersen H; Quint W; Xu L; Arbyn M; Bonde J
    J Clin Virol; 2020 Jul; 128():104336. PubMed ID: 32446166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.
    Bonde JH; Pedersen H; Quint W; Xu L; Arbyn M; Ejegod DM
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
    Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
    J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium.
    Bonde J; Ejegod DM; Cuschieri K; Dillner J; Heideman DAM; Quint W; Pavon Ribas MA; Padalko E; Christiansen IK; Xu L; Arbyn M
    J Clin Virol; 2018 Nov; 108():64-71. PubMed ID: 30253376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and analytical performance of the CLART HPV 4S assay with SurePath screening samples from the Danish cervical cancer screening program using the VALGENT framework.
    Ejegod DM; Pedersen H; Quint W; Xu L; Arbyn M; Bonde JH
    J Virol Methods; 2021 Jun; 292():114118. PubMed ID: 33766660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
    Oštrbenk A; Xu L; Arbyn M; Poljak M
    J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
    Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
    J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VALGENT: A protocol for clinical validation of human papillomavirus assays.
    Arbyn M; Depuydt C; Benoy I; Bogers J; Cuschieri K; Schmitt M; Pawlita M; Geraets D; Heard I; Gheit T; Tommasino M; Poljak M; Bonde J; Quint W
    J Clin Virol; 2016 Mar; 76 Suppl 1():S14-S21. PubMed ID: 26522865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
    Xu L; Oštrbenk A; Poljak M; Arbyn M
    J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.
    Ejegod DM; Lagheden C; Bhatia R; Pedersen H; Boada EA; Sundström K; Cortés J; Josë FXB; Cuschieri K; Dillner J; Bonde J
    BMC Cancer; 2020 May; 20(1):396. PubMed ID: 32375689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
    Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
    J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Performance of the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 Framework.
    Pedersen H; Ejegod DM; Quint W; Xu L; Arbyn M; Bonde J
    J Mol Diagn; 2022 Apr; 24(4):365-373. PubMed ID: 35123039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).
    Cuschieri K; Geraets D; Cuzick J; Cadman L; Moore C; Vanden Broeck D; Padalko E; Quint W; Arbyn M
    J Clin Microbiol; 2016 Sep; 54(9):2337-42. PubMed ID: 27385707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.
    Dhillon SK; Oštrbenk Valenčak A; Xu L; Poljak M; Arbyn M
    J Clin Microbiol; 2021 May; 59(6):. PubMed ID: 33731413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
    Geraets DT; Cuschieri K; de Koning MN; van Doorn LJ; Snijders PJ; Meijer CJ; Quint WG; Arbyn M
    J Clin Microbiol; 2014 Nov; 52(11):3996-4002. PubMed ID: 25210073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework.
    Heard I; Cuschieri K; Geraets DT; Quint W; Arbyn M
    J Clin Virol; 2016 Aug; 81():6-11. PubMed ID: 27262102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.
    Arbyn M; Simon M; Peeters E; Xu L; Meijer CJLM; Berkhof J; Cuschieri K; Bonde J; Ostrbenk Vanlencak A; Zhao FH; Rezhake R; Gultekin M; Dillner J; de Sanjosé S; Canfell K; Hillemanns P; Almonte M; Wentzensen N; Poljak M
    Clin Microbiol Infect; 2021 Aug; 27(8):1083-1095. PubMed ID: 33975008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Evaluation of INNO-LiPA HPV Genotyping
    Xu L; Padalko E; Oštrbenk A; Poljak M; Arbyn M
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection.
    Del Pino M; Alonso I; Rodriguez-Trujillo A; Bernal S; Geraets D; Guimerà N; Torne A; Ordi J
    J Virol Methods; 2017 Oct; 248():238-243. PubMed ID: 28739302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of EUROArray HPV test using the VALGENT framework.
    Viti J; Poljak M; Oštrbenk A; Bhatia R; Alcañiz Boada E; Cornall AM; Cuschieri K; Garland S; Xu L; Arbyn M
    J Clin Virol; 2018 Nov; 108():38-42. PubMed ID: 30223253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.